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Abstract
This study examined the impact of “New” and “#1 Prescribed” market claims and
quantitative efficacy information on perceptions of a hypothetical prescription drug in
a direct‐to‐consumer (DTC) print advertisement. We examined two market claims
(New and #1 Prescribed), two efficacy levels (higher and lower), and a control condition
without this information. Participants with diabetes were randomized to review one ad
version and asked their perceptions of the ad's message, the drug's benefits, side
effects and risks, doctors' opinions about the drug, and behavioral intention to use the
drug, as well as recall and recognition of drug benefits and risks. Results suggest the
market claim affects personal perceptions and perceptions of the ad's message about
drug benefits and perceptions about doctors' opinions of the drug. Inclusion of
quantitative information about product efficacy did not show a large influence on
perceptions. These findings can help inform stakeholders and policy makers as they
work to ensure DTC prescription drug promotion does not mislead patients.
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1 | INTRODUCTION
Direct‐to‐consumer (DTC) prescription drug advertisements are
monitored and studied by the US Food and Drug Administration
(FDA) in part due to the complexities of consumer interpretation of
drug ad content. The FDA states in their Presenting risk information in
prescription drug and medical device promotion: Draft guidance that
disclosure of risks and benefits associated with medical or
pharmaceutical treatment is important for informing consumer and
healthcare provider evaluations of safety and efficacy of therapeutic
treatments (FDA, 2009). Healthcare expansion and information
access via technology has drawn in more potential patients and
increased exposure to information about potential treatments and
diseases, enabling consumers to have more of an active role in their
healthcare decisions. Therefore, understanding consumer interpreta-
tion of DTC prescription drug advertising content is integral to
adapting to the changing public health landscape in the United States.
1.1 | Intrinsic and extrinsic cues
Companies (or sponsors) may choose to promote their prescription
drug products to consumers, healthcare providers, or both. The benefit
and risk information in prescription drug advertising created by the
company is primarily drawn from the FDA‐approved product labeling
for that product. However, the company marketing the drug product
may also choose to include information in ads such as price and market
status to promote their products, provided these claims are truthful
and non‐misleading. This information can be categorized as intrinsic,
relating to the physical product, or extrinsic, related to product image
and branding (Jacoby, Olson, & Haddock, 1971). Efficacy, dose, and
risk information are intrinsic cues that may be presented in drug ads.
There is an almost endless array of potential extrinsic cues, including
price, packaging, and celebrity endorsement (Lee & Lou, 2001). Market
claims are a particular type of extrinsic cue specific to the sales and
market status of the product, such as “best‐selling.” Intrinsic and
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extrinsic cues in drug ads have the potential to impact consumer
understanding of a drug's benefits, efficacy, and risks. In particular,
extrinsic cues may be accurate in content, but consumers' under-
standing of claim implications may lead to misinterpretations of a
drug's benefits, efficacy, and risks.
1.2 | Extrinsic cue: Market claims
Considerable work in advertising research shows that extrinsic
cues can be as powerful as or more so than intrinsic cues in
influencing consumer perceptions of product quality. For instance,
a common finding is that price is positively correlated with
perceived quality, even though price is negatively correlated with
willingness to buy. In other words, controlling for other product
traits, more expensive items are viewed more favorably (Dodds,
Monroe, & Grewal, 1991; Teas & Agarwal, 2000). Market claims
seen in DTC ads, such as “#1 Prescribed” and “New” are extrinsic
cues in that they do not refer to inherent properties of the
product. Importantly, while market claims such as price, drug
awareness, or duration in the market do not include explicit
information about efficacy, existing work indicates that such
claims do impact perceptions of drug benefits. For instance, in a
study of #1 Prescribed claims in DTC ads, Mitra, Swasy, and Aikin
(2006) found that consumers who saw this claim perceived the
product to be more effective and, when making judgments about
what doctors would think, rated the brand as more effective,
preferable, and trustworthy by doctors. Similarly, a comparative
efficacy claim (a claim stating one drug works better than another)
can increase consumers' comparative efficacy perceptions and
decrease perceptions of comparative risk (O'Donoghue et al.,
2014, Study 1). In both studies, consumers had no quantitative
efficacy information on which to base such judgments; thus, these
studies demonstrate that market claims carry drug benefit
connotations, which may or may not be supported.
1.3 | Intrinsic cue: Efficacy information
Efficacy information represents a type of intrinsic cue in that it
describes inherent properties of the product. Efficacy can be
thought of as the observed impact of a drug on health and might
be expressed in a numeric format (“78% of patients experience a
reduction in symptoms”) or a descriptive form (“most patients
experience a reduction in symptoms”). Supplying quantitative
efficacy information helps ameliorate consumers' tendency to
overestimate drug benefits (Schwartz & Woloshin, 2009; Schwartz,
Woloshin, & Welch, 2011). Other studies show including efficacy
information can facilitate understanding (O'Donoghue et al., 2014;
Sullivan, O'Donoghue, & Aikin, 2013). Taken together, research
indicates that providing consumers with efficacy information affects
both comprehension and perceptions. Therefore, it is important to
consider this specific intrinsic cue in the context of the overall drug
ad when examining factors that impact consumer perception of
prescription drugs.
1.4 | Consumer purchasing behavior
Zeithaml's “Means‐End” model (1988) offers a descriptive framework
of the factors, including intrinsic and extrinsic cues, that determine
consumer purchasing behavior. According to the model, both intrinsic
and extrinsic cues influence perceived quality of a product, which
refers to the consumer's judgment of a product's overall superiority
or excellence. The model also indicates that intrinsic and extrinsic
cues can influence perceived value, which refers to the consumer's
judgment of the monetary cost of the product. Extrinsic cues, in
particular, can serve as “value indicators,” which the author theorizes
is a powerful pathway to influence the final purchase decision.
Because value is the ultimate determinant of the purchase, an
efficient ad strategy might be to target value perceptions. Ziethaml
also posits that extrinsic cues are more generalizable across brands
and products than intrinsic cues.
1.5 | Consumer cost‐benefit analysis
As another consideration, consumer perception and understanding of
value is based on an individual's own cost‐benefit analysis. According
to Teas and Agarwal (2000), consumers evaluate products based on
two value properties: (a) Acquisition value and (b) transactional
value. Acquisition value is the net gain or tradeoff from consuming a
good or service. Transactional value refers to psychological satisfac-
tion with a financial deal. From a cost‐benefit perspective, consumers
perceive higher priced products to be of higher quality. Brand
advertising satiates the acquisition value concept because the
perceived benefits of a high‐quality drug may outweigh potential,
inexpensive alternatives, and justify the cost. However, consumers
perceive generic drugs to be a better value than brand name drugs
and few report concerns about safety or side effects of generic drugs
(Shrank, Cox, Fischer, Mehta, & Choudhry, 2009). The transactional
value principal can be applied to a consumer's satisfaction with a
discount on a highly marketed brand name product (coupon effect),
as the consumer receives a perceived high‐quality good for only a
fraction of the cost. Thus, positive price‐quality linkages may drive
consumer choice (Teas & Agarwal, 2000).
1.6 | Individual differences
The impact of market claims on consumers is not universal. Rather, a
variety of individual and situational factors interact with an ad's claims.
Knowledge about the product can interact with extrinsic and intrinsic
information. Extrinsic factors in general yield greater impact on
consumers who are less familiar with the product (Lee & Lou, 2011).
For instance, name brand (extrinsic cue) carries less weight among
consumers who are knowledgeable about the product category (Bett-
man & Park, 1980). In contrast, less knowledgeable consumers may be
more influenced by extrinsic factors. A counter‐intuitive exception,
however, is the finding that more knowledgeable consumers are more
susceptible to the effect of price (extrinsic) on product quality (Park &
Moon, 2003). Involvement can also impact the effect of extrinsic and
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intrinsic cues. High situational involvement is associated with less
reliance on extrinsic cues, in favor of intrinsic cues (Lee & Lou, 2011).
Together, these findings suggest that both knowledge and involvement
promote reliance on intrinsic cues to guide decisions.
1.7 | The present study
As healthcare and medical services become more patient‐driven, the
importance of accurately informing consumers of the risks and
benefits associated with therapies increases. The purpose of the
present research is to examine the impact of both market claims and
quantitative efficacy information in print advertising for prescription
drugs. This builds on prior work (Mitra et al., 2006; O'Donoghue
et al., 2014) to examine the interaction between market claims and
efficacy information on consumers' perceptions of prescription drugs.
We examined the following research questions:
Research Question 1: What effect do market claims (New or #1
Prescribed) have on perceptions of drug risks and benefits?
Research Question 2: Do perceptions vary by the presence of
quantitative efficacy information, and by the efficacy level
presented (a lower or higher efficacy level)?
Research Question 3: Does adding quantitative efficacy information
change the impact of the market claim on perceptions of drug risks
and benefits?
Research Question 4: Do demographic variables and other individual
differences affect drug perceptions and intentions?
2 | METHOD
2.1 | Participants
Participants were recruited from an opt‐in online panel and consisted of
525 adults who self‐identified as having been diagnosed with diabetes by
a doctor or healthcare provider, excluding diabetes during pregnancy
(gestational diabetes). Individuals who reported working in the health-
care, marketing, advertising, or pharmaceutical industries were excluded.
To get enough participants whomet the above inclusion criteria, a sample
of panelists (n=4,966) were invited via email to participate. We provided
one email reminder during the course of the survey. Of those invited,
22% (n=1,093) responded to the invitation and entered the survey site.
Participants first answered screener questions to determine eligibility.
Eligible participants were then shown consent language and invited to
continue. Ineligible participants were thanked and exited from the survey.
The rate of participants who screened in and consented was 62% (see
Consort Diagram below in Figure 1).
2.2 | Procedure
The study was conducted online via the Ipsos survey platform. Panelists
who had been pre‐identified as having diabetes were emailed a study
invitation. Participants were pre‐identified by self‐reporting on other
panel‐wide demographic measures whether they had ever been
diagnosed with diabetes by a physician or other qualified medical
professional. After participants completed screening and provided
consent, they were randomly assigned to view one of nine versions of
a DTC ad for a fictitious prescription drug to treat diabetic nerve pain,
Nuramen (see Appendix A). To ensure realism, the claims and the efficacy
information in the ad were constructed in consultation with a regulatory
review officer from FDA's Office of Prescription Drug Promotion. The
introductory language read: “On the next screen, you will see an ad for a
drug. The name of the drug has been changed for this study. Even though
it is on a computer screen, please read the ad as if it were in a magazine.
Imagine that the ad is for a product in which you might be interested.”
We used several strategies to encourage participants to read all
of the information in the ad: (1) The instructions encouraged
participants to pay close attention to the ad because they would
be asked questions about it, (2) the stimuli page included an option to
enlarge the ad, and (3) participants were asked if they had problems
viewing the ad. Participants who reported that they could not view
the ad were terminated from the survey. After viewing the ad,
participants were asked to complete an online survey which included
questions about their perceptions of the product's risks and benefits
and the market claim, measures of health literacy and numeracy, and
demographic information.
F IGURE 1 Consort diagram. *Quota met refers to when the total
number of participants within demographic categories are met to
have a balanced sample [Color figure can be viewed at
wileyonlinelibrary.com]
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We conducted cognitive interviews and pretesting to evaluate
the comprehensibility of the measures and to refine the stimuli. The
two independent variables of interest were type of market
claim (#1 Prescribed, New!, or No claim) and level of efficacy
information (Higher [72%], Lower [46%], or No efficacy). Efficacy
information was operationalized in the form of realistic quantitative
information (e.g., “46% of patients taking Nuramen felt their nerve
pain reduced by at least half (50%), compared with baseline”).
2.3 | Measures
2.3.1 | Recall
Participants were asked three open‐ended questions to assess recall
for the main message of the ad, the benefits of the drug, and the risks
and side effects of the drug. Responses were later coded for
accuracy.
2.3.2 | Recognition
Participants were asked to identify “Which of the following
statements, if any, were in the prescription drug ad you saw?” for
the market claim and the efficacy claim. For the drug's benefits, risks
and side effects, participants were asked “Read each statement and
indicate whether or not each of the following was mentioned as a
benefit [side effect or risk] of taking Nuramen. Even if you think a
statement is true, please select “Yes” only if it was written in the ad.”
Correct responses for the market claim and efficacy claim were
coded 1 = correct, 0 = incorrect. Responses for the benefit claims
were summed to create a score from 0 to 6. Responses for the risk
and side effect claims were summed to create a score from 0 to 6.
2.3.3 | Behavioral intention
Participants rated five statements, “Based on the prescription drug
ad, please rate how likely or unlikely you would be to take each of the
following actions if you saw such an ad in a magazine” (1 = not at all
likely, 6 = extremely likely):
• Look for information about Nuramen.
• Talk with a friend or family member about Nuramen.
• Ask your doctor for more information about Nuramen.
• Ask your doctor to prescribe Nuramen.
• Take Nuramen if your doctor prescribed it.
We created a measure of behavioral intention of these items
(Cronbach's α = 0.92).
2.3.4 | Perception measures
We measured both participants' personal perceptions of drug risk and
benefit, and their perceptions of the ad's message about drug risk and
benefit.
Ad risk perceptions
Participants were asked to rate their perceptions of the ad's message
about risks on three items (α = 0.71); “What is the ad's message about
how serious Nuramen's side effects are?” (1 = not at all serious,
6 = extremely serious), “What is the ad's message about how likely it is
that you would experience at least one side effect if you took
Nuramen?” (1 = not at all likely, 6 = extremely likely), “In your opinion,
what is the ad's message about the overall risk of Nuramen?” (1 = not
at all risky, 6 = extremely risky).
Personal risk perceptions
Participants rated their own interpretation of the drug's risks and
side effects on four items (α = 0.81); “In your opinion, how likely is it
that you would experience at least one side effect if you took
Nuramen?” (1 = not at all likely, 6 = extremely likely). “In your opinion,
how serious are Nuramen's side effects?” (1 = not at all serious,
6 = extremely serious), “In your opinion, do you think Nuramen's side
effects would be short‐lived or long‐lasting?” (1 = short‐lived, 6 = long‐
lasting), and “How would you rate the overall risk of Nuramen?”
(1 = not at all risky, 6 = extremely risky).
Ad comparative risk perceptions
Participants rated their perceptions of the ad's message about the
risks of the drug compared with other diabetic nerve pain drugs on
two items (α = 0.89); “In your opinion, what is the ad's message about
whether the side effects of Nuramen would be less serious or more
serious than other diabetic nerve pain drugs?” (1 =much less serious,
7 =much more serious), “In your opinion, what is the ad's message about
whether Nuramen would have a smaller or larger number of side
effects compared with other diabetic nerve pain drugs?” (1 =much
smaller number of side effects, 7 =much larger number of side effects).
Personal comparative risk perceptions
Participants rated their own interpretation of the comparative risks of
the drug on two items (α = 0.91); “Do you think the side effects of
Nuramen would be less serious or more serious than other diabetic
nerve pain drugs? (1 =much less serious, 7 =much more serious), and “Do
you think Nuramen would have a smaller number or larger number of
side effects compared with other diabetic nerve pain drugs?” (1 =much
smaller number of side effects, 7 =much larger number of side effects).
Ad benefit perceptions
Participants were asked to rate their perceptions of the ad's message
about benefits on two items (α = 0.72); “What is the ad's message
about how much Nuramen would improve your diabetic nerve pain?”
(1 = no improvement, 6 = complete improvement), “In your opinion, what
is the ad's message about the overall quality of Nuramen?” (1 = very
poor quality, 6 = excellent quality).
Personal benefit perceptions
Participants rated their own interpretation of the drug's benefits on
two items (α = 0.78); “In your opinion, how much would Nuramen
improve your diabetic nerve pain?” (1 = no improvement, 6 = complete
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improvement), “How would you rate the overall quality of Nuramen?”
(1 = very poor quality, 6 = excellent quality). They were also asked to
estimate the likelihood of experiencing a benefit from the drug on a
single item; “In your opinion, if 100 people take Nuramen, how many
will experience relief from diabetic nerve pain?” (open‐ended,
number between 0 and 100).
Ad and personal comparative effectiveness perceptions
Participants rated their perceptions of the effectiveness of the drug
compared with other diabetic nerve pain drugs on two single item
measures, both in terms of the ad's message and their own
interpretation. “In your opinion, what is the ad's message about
whether Nuramen would be less effective or more effective than
other diabetic nerve pain drugs?” (1 =much less effective,7 =much
more effective), and “Do you think Nuramen would be less effective or
more effective than other diabetic nerve pain drugs?” (1 =much less
effective, 7 =much more effective).
2.3.5 | Perceptions of doctor's views
Participants rated their opinion about how their doctor would view
the benefits of the drug compared with other diabetic nerve pain
drugs on three items (α = 0.93); “Do you think doctors trust Nuramen
less or more than other diabetic nerve pain drugs?” (1 = trust Nuramen
much less, 7 = trust Nuramen much more), “Do you think doctors prefer
Nuramen less or more than other diabetic nerve pain drugs?”
(1 = prefer Nuramen much less, 7 = prefer Nuramen much more), “Do
you think doctors would rate Nuramen as less effective or more
effective than other diabetic nerve pain drugs?” (1 =much less effective,
7 =much more effective). Participants also rated their opinion of
doctors' beliefs about comparative benefits of the drug on two items
(α = 0.78); “How much do you think doctors believe Nuramen would
improve your diabetic nerve pain?” (1 = no improvement, 6 = complete
improvement), How do you think doctors would rate the overall quality
of Nuramen?” (1 = very poor quality, 6 = excellent quality), their opinions
of doctors' beliefs about the drug's risks on two items (α = 0.69); “How
serious do you think doctors believe Nuramen's side effect are?”
(1 = not at all serious, 6 = extremely serious), “Do you think doctors
believe that Nuramen's side effects would be short‐lived or long‐
lasting?” (1 = short‐lived, 6 = long‐lasting), and their opinion of doctors'
beliefs about comparative risks (α = 0.89); “Do you think doctors
believe that the side effects of Nuramen would be less serious or more
serious than other diabetic nerve pain drugs?” (1 =much less serious,
7 =much more serious), “Do you think doctors believe that Nuramen
would have a smaller number or larger number of side effects
compared with other diabetic nerve pain drugs?” (1 =much smaller
number of side effects, 7 =much larger number of side effects).
2.3.6 | Skepticism
Participants rated their skepticism on the item, “To what degree do you
believe the information written in the ad?” (1 = do not believe at all,
6 = completely believe).
2.3.7 | Attention
Participants were asked “How much attention did you pay to these
features of the ad?” (1 = did not pay attention at all, 6 = paid complete
attention). Features of the ad were then listed and included both
features that were actually in the ad (e.g., “the product logo” or “the
diagram of a foot”) as well as features that were not in the ad (e.g.,
“the picture of a Nuramen tablet”, “The phrase, 'Not tested on
animals””).
2.3.8 | Importance of drug attributes
Participants rated eight statements, “When you consider taking a
drug, how important are the following?” (1 = not at all important,
6 = extremely important):
• If the drug is new.
• How often the drug is prescribed for the condition.
• How many patients are helped by the drug, according to clinical
trials.
• If people I know recommend the drug.
• How many people with my medical condition use the drug.
• How often the drug is used, compared with other drugs in the
market that treat the same condition.
• The drug's side effects.
• The drug cost and/or copay.
• My doctor's recommendation.
2.3.9 | General perceptions of market claims
Participants rated their perceptions of the risk and efficacy of “New”
and “#1 Prescribed” drugs, “New drugs tend to be more effective than
drugs that have been in the market for a longer time,” “New drugs
tend to be less risky than drugs that have been in the market for a
longer time” (two items, α = 0.78), and “The #1 Prescribed drug tends
to be more effective than other drugs in the market,” and “The #1
Prescribed drug tends to be less risky than other drugs in the market”
(1 = strongly disagree, 7 = strongly agree; two items, α = 0.83).
2.3.10 | Condition status and medical knowledge
Participants rated the severity of their diabetes (1 = not at all severe,
6 = extremely severe), level of concern about the impact of diabetes
on their life (1 = not at all concerned, 6 = extremely concerned),
whether they were currently or had ever taken medication to treat
their diabetes (never taken, used to take, or currently taking), how
much they knew about the disease (1 = not at all knowledgeable,
6 = extremely knowledgeable), and how familiar they were with
treatments for diabetes (1 = not at all familiar, 6 = extremely familiar).
Participants were also asked if they had ever experienced nerve
pain from diabetes (never experienced, used to experience, or currently
experiencing), the severity of that pain (0 = no pain, 10 =worst
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possible pain), and whether they were currently or had ever taken
medication to treat their diabetic nerve pain (never taken, used to
take, or currently taking).
2.3.11 | Literacy and numeracy
We asked participants to answer two subjective health literacy items
(Cronbach's α = 0.36; Chew et al., 2008) and three objective numeracy
items (Cronbach's α = 0.48; Schwartz et al., 2009). Given the low
internal consistency between the two subjective health literacy items,
we used the item “How confident are you filling out medical forms by
yourself?” as a single item subjective health measure in our analysis
(Jordan, Osborne, & Buchbinder, 2011). Objective numeracy scores
ranged from 0 to 3, with higher numbers indicating greater numeracy.
Scores of 1 and below on this measure are considered low numeracy
(Schwartz et al., 2009).
3 | RESULTS
Analyses were conducted using SPSS 24.0. We conducted Chi‐square
analyses to examine differences in open‐ended responses. We
examined recall and recognition of main message elements first in
the full sample, then focused our analyses on participants who
correctly remembered seeing the appropriate market claim and
participants in the control group who correctly did not remember
seeing a market claim (focused sample). We did not see significant
differences between the demographics of the full and focused
sample. Study participants were primarily female (55%), white (92%),
non‐Hispanic (97%), and were on average age 62. Less than 40%
(39% full sample and 37% focused sample) had a high school degree
or less and 48% reported household income of $39,999 or less (see
Table 1).
Two‐way analyses of variance tests (ANOVAs) were then used to
test the impact of efficacy information and market claim on the
measures of interest. The two market claim conditions (“#1
Prescribed” and “New”) were analyzed in separate 2 × 3 ANOVAs,
which included two levels of market claim (the experimental claim
condition and the “None” control condition) and three levels of
efficacy information (None, Lower, and Higher).
In addition, we examined covariates (ANCOVA) to see if certain
demographic (health literacy, numeracy, age, and disease severity) or
attitudinal variables (importance of drug attributes and general
perceptions of market claims) had an effect on intention and
perceptions.
3.1 | Recall
3.1.1 | Main message recall
Overall, the majority of participants across all conditions freely
recalled that the main message of the ad was that the drug relieves or
controls nerve pain (see Table 2). The other top four categories of
recall were has side effects, relieves or controls pain, New, and relieves or
controls foot pain. Of note, only some participants were exposed to
the market claim “New,” and this analysis includes all participants.
Participants who saw the stimuli with the New claim without
efficacy information were more likely to recall a main message of the
product has side effects (17%) than those who saw the ad with higher
or lower efficacy information (5%, 2%; χ2 (2, 177) = 10.42, p = 0.005).
There were no differences between conditions for the #1 Prescribed x
Efficacy analysis (p > 0.05).
3.1.2 | Benefit and risk recall
Overall, participants recalled relieves or controls nerve pain, relieves or
controls pain, and relieves or controls foot pain most commonly as
benefits. Participants recalled dizziness, lightheadedness, fainting,
swelling, nausea, rash, hives, or blisters, and headaches most commonly
as risks. Of note, don't know responses exceeded recall of risks and
benefits in some cases. Eighteen percent (18%) of participants
responded don't know/don't care/too many when asked to recall risks,
which is a larger frequency than four of the top five recalled risks,
and 12% of participants responded none/don't know when asked to
recall drug benefits. Recall of product benefits and risks did not differ
across conditions, all p's > 0.05.
TABLE 1 Demographics of the study sample
Mean (SD) or percent
Full sample Focused sample
Demographic variable (n = 525) (n = 360)






Hispanic or Latino 3.2% 3.3%
Race
White 91.8% 91.1%








Income (Total combined family income during 2016)





$100,000 or more 12.4% 13.9%
Education (highest level of school completed)




Some college but no degree 20.0% 18.6%
Associate degree in college 11.0% 12.8%
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3.2 | Recognition
3.2.1 | Market claim and efficacy
A significantly higher proportion of participants who viewed an ad with
a market claim correctly recognized the market claim, whether New or
#1 Prescribed, χ2(2, 525) = 20.64, p < 0.001 and χ2(2,525) = 66.18,
p < 0.001, respectively. Of the 177 participants who viewed an ad with
a New market claim, 69.5% correctly recognized that claim. Of the 174
participants who viewed an ad with a #1 Prescribed market claim,
47.1% recognized that claim. Likewise, across conditions, a significantly
higher proportion of participants who viewed an ad mentioning
efficacy level reported seeing the correct efficacy level: No efficacy,
χ2(2, 525) = 82.62, p < 0.001; lower efficacy, χ2(2,525) = 81.06, p < .001;
and higher efficacy, χ2(2,525) = 53.39, p < 0.001. Of the 164 partici-
pants who were in the No Efficacy condition, 54.3% selected the
correct answer on the efficacy recognition item. Among the 182
participants in the Lower Efficacy condition, 54.9% selected the
correct answer. Of the 179 participants in the Higher Efficacy
condition, 55.3% selected the correct answer.
3.2.2 | Benefit and risk
Table 3 provides a breakdown of the responses to the recognition of
product benefits and risks. Participants showed high recognition of
the benefit “Relieves diabetic nerve pain” and moderate recognition
of the benefit “Most patients reported that they felt better and could
do more.” Less than a third of participants recognized the benefit
“Can be taken with or without food.” The number of correct
responses were summed to create a benefit accuracy score (0–3).
For the total sample, the mean benefit accuracy score was 1.80 out of
3 (SD = 0.86). Recognition of benefits did not differ by market claim
or efficacy level (all p's > 0.30).
Recognition was high for two drug risks present in the ad
(dizziness and allergic reaction), but only a third of participants
recognized the risk of addiction. The number of correct responses
were summed to create a risk accuracy score (0–3). For the total
sample, the mean risk accuracy score was 1.85 out of 3 (SD = 0.95).
There was a main effect of efficacy (F(2, 340) = 3.08, p = 0.05), which
was qualified by a significant interaction of #1 Prescribed market
claim and efficacy, F(2, 340) = 3.40, p = 0.04, p
2η = 0.02 (see Figure 2).
Participants who did not see a market claim recognized fewer risks
when the ad included low efficacy (M = 1.52, SD = 0.96), compared
with no efficacy (M = 2.13, SD = 0.75).
There was also an effect of New claim, F(1, 341) = 4.67, p = 0.01,
p
2η = 0.03. Participants who saw the New claim correctly recognized
more risks (M = 1.88, SD = 0.94) compared with participants who saw
no claim (M = 1.86, SD = 0.94).
As described above, we conducted the following analyses only on
participants who accurately recognized the market claims, so
comparisons in this section describe comparisons between partici-
pants who accurately remembered the market claim versus
participants who accurately did not remember a market claim
(control). Supplementary Table 4 presents the means and standard
deviations for each of the following measures.








Has side effects 9 (46)
Relieves/controls pain 8 (44)
New 8 (42)




Relieves/controls pain 24 (126)











Note. Percentages may add to more than 100% because multiple
responses were permitted.
TABLE 3 Percentage of correct and incorrect responses to benefit and risk recognition items
Item % Correct (N)
Benefits Relieves diabetic nerve pain [accurate] 93.3 (460)
Can be taken with or without food [accurate] 29.7 (156)
Relieves problems with urination [inaccurate] 90.7 (476)
Reduces indigestion, nausea, or vomiting [inaccurate] 87.4 (459)
Most patients reported that they felt better and could do more [accurate] 56.2 (295)
Safer than other drugs for nerve pain associated with diabetes [inaccurate] 52.6 (276)
Risks Dizziness [accurate] 76.6 (402)
Allergic reaction [accurate] 73.9 (388)
Addiction [accurate] 33.7 (177)
Blurred vision [inaccurate] 63.4 (333)
Diarrhea [inaccurate] 55.8 (293)
Dry mouth [inaccurate] 70.5 (370)
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3.3 | Behavioral intention
There were no significant effects on behavioral intention (all p's > 0.09).
This did not change when attitudinal covariates were added to the model.
When selected demographic covariates were considered, we found that
participants in the #1 Prescribed condition reported higher behavioral
intention (M=3.51, SD=1.57) than participants in the control condition
(M=3.15, SD=1.46), F(1, 227) = 4.93, p=0.03, p
2η =0.02.
3.4 | Perceptions of product risks
There were no significant effects of perceptions of the ad's message
about risks (all p's > 0.07), personal perceptions of risk (all p's > 0.50),
perceptions of the ad's message about the risk of the product compared
with other products that treat the condition (all p's > 0.08), personal
perceptions of comparative risk (all p's > 0.40), beliefs about doctor's
perception of product risk (all p's > 0.30), or beliefs about doctor's
perception of comparative risk (all p's > 0.30). These results did not
change when demographic or attitudinal covariates were considered.
3.5 | Perceptions of product benefits
We found several main effects of market claim on perceptions of drug
benefits. With the exception of perceptions of likelihood of experien-
cing a benefit from the drug, there were no significant differences
between efficacy levels, nor were there significant interactions
between the market claim and efficacy experimental conditions.
3.5.1 | Ad message about benefits
Participants who saw the #1 Prescribed claim rated the ad's message
about the drug benefits as greater (M=4.95, SD= 0.64) than those who
saw no claim (M=4.46, SD=0.99), F(1,231) = 15.10, p<0.001, p
2η =0.06.
There were no significant effects for the New claim (all p's > 0.30). These
effects did not change when demographic or attitudinal covariates were
added to the model.
3.5.2 | Ad message about comparative
effectiveness
Participants who saw the #1 Prescribed claim rated the ad's message
about the effectiveness of the drug compared with other products
that treat the condition higher (M = 6.13, SD = 0.90) than those who
saw no claim (M = 5.35, SD = 1.37), F(1, 231) = 20.93, p < 0.001,
p
2η = .08. There were no effects of the New claim (all p's > 0.30).
These effects held when demographic and attitudinal covariates were
examined.
3.5.3 | Personal perceptions of benefits
Participants in the #1 Prescribed claim condition rated their personal
perceptions of drug benefits as greater (M = 4.37, SD = 0.97) than
those in the control condition (M = 3.86, SD = 1.14), F(1, 231) = 10.83,
p = 0.001, p
2η = 0.05. Participants in the New claim condition also
rated their personal perceptions of drug benefits as greater
(M = 4.13, SD = 1.02) than those in the control condition (M = 3.86,
SD = 1.14), F(1, 272) = 4.22, p = 0.04, p
2η = .02. These effects did not
change when demographic or attitudinal covariates were added.
3.5.4 | Personal perceptions of comparative
effectiveness
Participants in the #1 Prescribed claim condition (M = 5.51, SD = 1.10)
and the New condition (M = 5.15, SD = 1.18), rated the drug as more
effective compared to other diabetic nerve pain drugs, as compared
with the control condition (M = 4.90, SD = 1.24), F(1,231) = 13.05,
p < 0.001, p
2η = 0.05 and F(1,268) = 3.88, p = 0.05, p
2η = 0.01, respec-
tively. These effects remained significant when demographic covari-
ates were considered. When attitudinal covariates were examined, the
effect of the New claim became nonsignificant (p = 0.11).
3.5.5 | Likelihood of benefits
Participants in the #1 Prescribed claim condition rated the likelihood
of experiencing a drug benefit as higher when they saw a higher
efficacy claim (M = 66.78, SD = 18.95) than those who saw the lower
efficacy claim (M = 55.78, SD = 21.97) or no claim (M = 60.33, SD =
26.16), F(2, 231) = 4.14, p = 0.02, p
2η = .04. These effects did not change
when demographic or attitudinal covariates were added to the model.
Participants in the New claim condition or control condition
estimated the likelihood of experiencing a drug benefit as higher when
they saw a higher efficacy claim (M = 66.21, SD = 19.85), compared
with those who saw lower efficacy (M = 57.66, SD = 21.67), or no
efficacy claim (M = 61.86, SD = 25.06), F(2, 272) = 3.35, p = 0.04,
p
2η = .02. When demographic covariates were added, additional main
effects emerged. Participants in the New claim or control conditions
F IGURE 2 Mean risk recognition by market claim and efficacy
level [Color figure can be viewed at wileyonlinelibrary.com]
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estimated the likelihood of experiencing a benefit from the drug as
higher (M= 64.63, SD = 20.02) compared with participants who saw no
claim (M = 59.75, SD = 23.96), F(1, 268) = 4.09, p = 0.04, p
2η = 0.02.
Similarly, when attitudinal covariates were considered, participants
in the New claim or no claim conditions estimated the likelihood of
experiencing a benefit from the drug as higher (M = 64.63, SD = 20.02)
compared with participants who saw no claim (M = 59.75, SD = 23.96),
F(1, 270) = 3.88, p = 0.05, p
2η = 0.01.
3.6 | Perceptions of doctor beliefs about benefits
Participants in the #1 Prescribed condition rated doctors' perceptions of
drug benefit higher (M=4.74, SD=0.90) than those who saw no claim
(M=4.22, SD=0.99), F(1, 231) = 15.10, p<0.001, p
2η =0.06, and rated
doctors' beliefs about the benefit of the drug compared with other
products higher (M=5.02, SD=1.06) than those who saw no claim
(M=4.43, SD=1.10), F(1, 231) = 16.19, p<0.001, p
2η =0.07. There were
no effects of the New claim (all p's > 0.20). These effects did not change
when demographic or attitudinal covariates were added to the model.
3.7 | Skepticism
Participants in the #1 Prescribed condition were more skeptical of the
information in the ad (M=4.32, SD=1.08) compared with participants
who saw no claim (M= 3.82, SD=1.28), F(1, 231) = 8.61, p<0.005,
p
2η =0.04. There were no effects of the New claim (all p's > 0.20). These
effects did not change when demographic or attitudinal covariates were
added to the model.
3.8 | Attention to market and efficacy claims
For each respondent, we calculated mean attention paid to the
accurate items and normalized the score based on the total number
of items shown to the participant, as the total number differed by
condition. Participants in the #1 Prescribed condition reported
paying more attention to claims (M = 3.93, SD = 1.11) than those who
did not see a claim (M = 3.54, SD = 1.23), F(1, 231) = 5.53, p = 0.02,
p
2η = 0.02. There were no effects of the New claim (all p's > 0.06).
4 | DISCUSSION
Our first research question examined the effect that market claims
have on perceptions of drug risks and benefits. We observed effects
of market claims on participant perceptions of the ad's message and
their own perceptions about the drug's benefits, the effectiveness of
the drug compared with other similar drugs, and perceptions of
doctor beliefs about drug benefits. Regardless of the type of efficacy
information in the ad, those who saw an ad with a market claim rated
the drug's benefits higher than those who did not see a market claim,
particularly if the claim was #1 Prescribed. However, the presence of
the #1 Prescribed market claim resulted in greater skepticism about
the information in the ad. These findings partially support previous
research which found that ads with market claims implied greater
effectiveness (Mitra et al., 2006). We did not observe any effects of
market claim on risk perceptions. We also found that the two market
claims did not impact perceptions equally. The #1 Prescribed claim
had more impact on perceptions of drug benefit than the New claim,
suggesting that these two claims communicate different information
to consumers.
Based on our second research question, we examined whether
perceptions varied by the presence of efficacy information and level
of efficacy presented. Participants in the Higher efficacy condition
thought that significantly more people would experience diabetic
nerve pain relief with Nuramen, as compared with the Lower efficacy
condition or no efficacy condition for both of the market claims.
Including efficacy information about the drug changes perceptions
about benefit likelihood only when the efficacy is higher, compared
with lower or no information at all. This suggests that including
information about how well the drug works may allow consumers to
have a more accurate perception of their likelihood of experiencing a
benefit and contribute to making informed decisions about the
treatment (O'Donoghue et al., 2014; Schwartz, Woloshin, & Welch,
2009). Although recall of drug benefits and risks did not vary by
market claim or efficacy level, we did see some effects for
recognition. Participants who saw the New claim correctly recog-
nized more risks compared with participants who saw no claim.
Further, when examining the #1 Prescribed claim, participants who
did not see a market claim recognized fewer risks when the ad
included low efficacy, compared with no efficacy information.
Our third research question explored whether quantitative
efficacy information changed the impact of the market claim on
perceptions of the drug's risks and benefits. We found limited
evidence here. When a claim of #1 Prescribed was present,
participants recognized more risks when efficacy information was
absent, compared with when low efficacy information was included.
The presence of efficacy information did not interact with the
presence of the market claim on our other measures.
Our fourth and final research question explored whether certain
selected demographic variables (health literacy, numeracy, age, and
disease severity) and attitudinal variables (importance of drug
attributes and general perceptions of market claims) affected
perceptions and intentions. We found some influence of covariates
on our results. In the model containing the New market claim, the
addition of demographic variables influenced behavioral intentions,
and both attitudinal and demographic variables influenced percep-
tions of benefit likelihood. This suggests that the way people perceive
the New market claim may be influenced by personal characteristics
and pre‐existing attitudes about prescription drugs or market claims
themselves.
There are several limitations to this study. First, the sample is not
designed to be broadly generalizable to the diabetes population in the
USA. For example, the sample has more women, more people who
identify as white, and is more highly educated than the US diabetes
population. Second, only individuals with diabetes were included in
this study, and the study tested advertisements for a hypothetical drug
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to treat diabetic nerve pain. Although diagnosis of the medical
condition treated by the drug can function as a proxy for involvement,
the findings may not generalize to individuals without diabetes or to
drugs that treat conditions other than diabetic nerve pain. Third, this
study was conducted using an online methodology. Although this is not
unusual (the majority of studies of this type are now being conducted
online), it is possible that irrespective of study format, participants
were distracted and did not devote their full attention to the survey. It
is also the case that consumers are encountering this type of
information in multiple ways, including online, lending support to the
assertion that the results are not due solely to the method of
administration. Fourth, we found better recognition accuracy for the
New claim than for the #1 Prescribed claim in our manipulation
checks. Although we did pretest the stimuli to promote recognition for
both the market and efficacy claims, and held the font, color, and
location of the claims constant across conditions, it is possible that
despite our efforts to make the claims very noticeable, the #1
Prescribed claim was not as salient for participants.
Future research could be conducted with different populations,
such as a general population sample, a healthcare professional
sample, or with individuals who exhibit low health literacy or low
numeracy, to test the generalizability of the findings. In addition,
other types of market claims may have different effects on consumer
behavioral intentions and perceptions of risk and benefit. Future
research could also test the external validity of the present findings
by incorporating market claim and efficacy information into exist-
ing ads.
4.1 | Conclusion/implications
DTC prescription drug advertising elicits both praise and criticism
from consumers and the medical advertising community. Although
DTC pharmaceutical advertising can motivate consumers to seek
medical information and make informed choices about medical
treatments, potential adverse effects exist. Market leadership claims
can lead some consumers to overestimate the effectiveness of a
brand name pharmaceutical treatment in comparison with a generic
or lesser known medication with similar properties (Mitra et al.,
2006). Similarly, the results of our study indicate that personal
perceptions and perceptions of an ad's message about drug benefits
and perceptions about doctors' opinions of a drug may be unduly
influenced by market leadership claims. Future research should
explore the potential impact on patient–physician relationships
because expected outcomes of drug efficacy may increase patient
demands for certain pharmaceuticals, in some cases leading to
inappropriate prescribing decisions (Young, Lipowski, & Cline, 2005).
A final, recurring theme in the literature is that some feel that risk
information, in particular, is not adequately explained in DTC
pharmaceutical advertisements (Kees, Bone, Kozup, & Ellen, 2008).
Understanding the linkages between DTC prescription drug
advertising and consumer perception, and comprehension is useful
in guiding public policy for pharmaceutical safety and advertising. In
addition to the influence market claims and various types of efficacy
presentations have on consumer perception, as highlighted by our
study; factors like imagery and the appearance of the people in ads
also influence perceptions of drugs (Cline & Young, 1991). Extrinsic
cues, like the esthetic components of advertisements coupled with
emotional and social appeals, heavily affect consumers' abilities to
rationalize and fully comprehend advertising content (Tsai &
Lancaster, 2012). And as this study and others have shown, these
extrinsic cues can have a more powerful impact on consumer
perceptions than intrinsic cues like dosing, risk, or efficacy informa-
tion. As consumers become more involved in the healthcare decision‐
making process, special attention should be given to DTC prescrip-
tion drug promotion and the many nuances that impact consumer
comprehension and perception. This provides both an opportunity
and a challenge for regulatory agencies and policy advocates to
ensure DTC prescription drug promotion informs and does not
mislead patients.
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